Introduction
============

The global prevalence of obesity has increased rapidly in recent years, and the number of overweight or obese adults worldwide is expected to reach 3.3 billion by 2030 ([@ref-20]). The rapid increase in obesity worldwide will lead to an increasing in related health complications, including insulin resistance, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease and cardiovascular disorders. Accumulating animal and human research evidence implicates obesity and related metabolic disturbances as the major risk factors for the development of insulin resistance and T2DM ([@ref-33]). Obesity is a chronic, low-grade inflammation that increases various inflammatory reactions related to body fat ([@ref-32]). White adipose tissue (WAT), a very important endocrine organ, consists mainly of subcutaneous adipose tissue (SAT) and internal adipose tissue. Internal adipose tissue makes up approximately 20% of the total body fat mass and mainly consists of visceral adipose tissue (VAT). In obesity, inflammation can occur due to increased levels of chemokines (such as CCL2 and CXCL1) and inflammatory cytokines (such as tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6)) secreted from accumulated fat in hepatocytes and adipocytes, causing insulin resistance ([@ref-22]; [@ref-41]). In obesity, macrophage infiltration in adipose tissue was observed in both rodents and humans ([@ref-11]; [@ref-15]; [@ref-27]). Macrophages are important immune cells, and the activation of macrophages could release various cytokines that promote the development of insulin resistance ([@ref-31]; [@ref-44]). The above studies indicate that reducing the levels of chemokines, secreted inflammatory cytokines and macrophage infiltration in VAT may alleviate obesity-induced insulin resistance and its progression.

CC-chemokine receptor 2 (CCR2), a receptor for monocyte chemoattractant proteins (MCPs), plays a pivotal role in the entry of innate immune cells into tissue and influences systemic insulin resistance and adipose tissue inflammation associated with obesity in high-fat-fed murine models ([@ref-40]). Studies have demonstrated that CCR2 deficiency could reduce the migration of macrophages in adipose tissue ([@ref-3]). Pharmacological inhibition of CCR2 can reduce inflammation in adipose tissue, alter hepatic metabolism and ameliorate multiple diabetic parameters in mouse models of T2DM and high-fat diet (HFD)-fed mice ([@ref-23]; [@ref-37]). Moreover, deficiency of CCR2 in macrophages alleviates inflammation of adipose tissue and the associated metabolic syndrome (abnormal glucose tolerance, insulin sensitivity profiles and hepatic steatosis) in obese mice ([@ref-21]). Resveratrol (RES, 3,4′,5-trihydroxystilbene) is a polyphenol mainly found in grapes, mulberries and red wine, and it provides many health benefits including cardioprotective and anti-inflammatory effects. RES inhibits monocyte CCR2 binding activity and expression in a NO-, MAPK- and PI3K-dependent manner in THP-1 monocytes ([@ref-7]). Furthermore, RES metabolites showed anti-inflammatory properties via regulating chemokines in a lipopolysaccharide-activated U-937 macrophage model ([@ref-35]). Recent studies demonstrated that RES ameliorates inflammation and insulin resistance in murine models of obesity induced by a HFD ([@ref-8]; [@ref-30]; [@ref-43]). However, whether RES treatment could inhibit macrophage infiltration and regulate insulin signaling in insulin-sensitive WAT in obesity is still unknown.

Considering the key role of the innate immune system in obesity-induced inflammation, the regulatory function of CCR2 on inflammation and the recruitment of macrophages to insulin-sensitive tissues in response to HFD-induced obesity, we investigated the role of CCR2 in abnormal glucose disorder and inflammation of adipose tissue induced by HFD. We also determined whether RES administration would alleviate inflammation and the effects of disordered glucose metabolism induced by HFD treatment by inhibiting CCR2 expression and enhancing insulin sensitivity in VAT and SAT in obese mice.

Materials and Methods
=====================

Chemicals and reagents
----------------------

Resveratrol (3,4,5-trihydroxy-trans-stilbene) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL) assay kits for estimation of TG, cholesterol, HDL and LDL in serum were purchased from BIOSINO Bio-technology and Science Inc. (Beijing, China). An insulin ELISA kit was obtained from Bai Wo (Shanghai, China). TRIzol and the oligonucleotides for PCR were obtained from Invitrogen, Inc. (Carlsbad, CA, USA), and a real-time quantitative PCR kit was purchased from TAKARA Bio, Inc. (cat. RR037A and RR420A; Otsu, Shiga, Japan). Mouse anti-β-actin antibody (cat. A5441) was obtained from Sigma-Aldrich (St. Louis, MO, USA), rabbit anti-Akt (protein kinase B) (cat. 4691T), rabbit anti-phosphorylated (p)-Akt (phosphorylated at Ser^473^) (cat. 4058T), rabbit anti-insulin receptor substrate 1 (IRS-1) (cat. 2390S) and rabbit anti-glucose transporter 4 (GLUT4) (cat. 2213S) antibodies were purchased from Cell Signaling Technology (Billerica, MA, USA). Rabbit anti-CCR2 antibody (cat. DF2711) and goat anti-rabbit IgG (H+L)-HRP (cat. S0001, dilution, 1:5,000) and goat anti-mouse IgG (H+L)-HRP (cat. S0002, dilution, 1:5,000) secondary antibodies were purchased from Affinity Biosciences, Inc. (Cincinnati, OH, USA). All other chemicals were of the highest grade commercially available.

Animals and animal care
-----------------------

A total of 40 6-week-old male C57BL/6 mice (19--25 g) were purchased from the Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All animals were maintained at 21 °C on a 12 h light/12 h dark cycle and were allowed access to food and water ad libitum. The protocols and the use of animals were approved by and in accordance with the Xinxiang Medical University Animal Care and Use Committee (XXMU-2016-0007). The animals were treated humanely and with regard for alleviation of suffering.

Experimental design
-------------------

After one week of acclimation, all mice were randomly divided into four groups (*n* = 10) and treated for 18 weeks as follows: (1) the standard chow diet (STD) group was fed a STD; (2) the HFD group was fed a HFD (41.26% of calories from fat); (3) the HFD-RES/L group was fed a HFD and treated with RES (200 mg/kg/day); and (4) the HFD-RES/H group was fed a HFD and treated with RES (400 mg/kg/day). The L and H in RES/L and RES/H stand for low and high, respectively. The doses of RES treatment (200 and 400 mg/kg/day) are based on those used in previous studies ([@ref-10]; [@ref-24]). The HFD intervention and RES treatment were started simultaneously. RES was dissolved in 0.1 mL deionized water and administered to the treatment groups daily (9:00 a.m.) by oral gavage, and the mice in the STD group and HFD group were administered with 0.1 mL deionized water by oral gavage at the same time. The RES and deionized water were administered seven consecutive days per week for 18 weeks. The macronutrient contents of the STD and the HFD are shown in [Table 1](#table-1){ref-type="table"}, and the ingredient composition of the HFD was as follows (w/w): standard chow, 60%; custard powder, 8%; lard, 12%; sugar, 12%; peanut powder, 6%; and milk, 1% ([@ref-9]). The mice were weighed each week.
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###### The energy supply for the standard chow diet (STD) and the high-fat diet (HFD).
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        Fat (%)   Carbohydrates (%)   Protein (%)   Total energy (kcal/g)
  ----- --------- ------------------- ------------- -----------------------
  STD   13.68     64.44               21.88         3.29
  HFD   41.26     39.61               19.13         4.59

**Note:**

STD, standard chow diet; HFD, high-fat diet.

After 18 weeks of treatment, mice were sacrificed by intravenous pentobarbital injection (20 mg/kg). Abdominal SAT and VAT (perirenal) were collected, weighed, immediately frozen in liquid nitrogen and stored at −80 °C for future experiments. The remaining SAT and VAT were fixed in a formaldehyde solution for histology and immunohistochemistry. The SAT coefficient and VAT coefficient were calculated (SAT weight and VAT weight × 100/body weight, respectively).

Blood glucose homeostasis and insulin resistance
------------------------------------------------

After 17 weeks of treatment, the intraperitoneal glucose tolerance test (IPGTT) was conducted in the mice as previously described ([@ref-26]). Briefly, mice were fasted for 10 h, and glucose (1 mg/g body weight) was injected intraperitoneally for IPGTT. Blood samples were collected from the tail vein and blood glucose measurement was conducted with a commercial hand-held glucometer (Accu-Chek Active; Roche, Shanghai, China) at the indicated time points (0, 15, 30, 60, and 120 min). Additionally, the area under the curve (AUC), an index of glucose tolerance, was calculated. The homeostasis model assessment for insulin resistance index (HOMA-IR) was calculated using the formula HOMA-IR = (fasting serum insulin concentration) × (fasting serum glucose concentration)/22.5 ([@ref-9]), and the insulin sensitivity index (ISI) was calculated as follows: 1/ln (fasting serum insulin concentration × fasting serum glucose concentration) ([@ref-39]).

Analysis of metabolic parameters
--------------------------------

At the end of the treatment (18 weeks), blood was collected from mice that had been fasted for 12 h. Serum was obtained after centrifugation (1,000×*g* for 10 min at 4 °C) (Eppendorf 5810R, Hamburg, Germany). The levels of TG, TC, HDL and LDL in serum were assayed using enzymatic colorimetric assays (BIOSINO Bio-technology and Science, Inc., Beijing, China) according to the manufacturer's instructions.

Measurement of serum cytokines, leptin, adiponectin and insulin by ELISA
------------------------------------------------------------------------

Serum insulin was determined using a commercial mouse ELISA kit (Bai Wo Bio-technology, Shanghai, China). TNF-α, MCP-1 and IL-6 levels in serum were measured by mouse ELISA kits (R&D Systems, Billerica, MA, USA) according to the manufacturer's protocols.

Immunohistochemistry
--------------------

Subcutaneous adipose tissue and VAT were fixed overnight at room temperature in formaldehyde solution (4%), dehydrated, and embedded in paraffin. Immunohistochemistry for macrophage marker F4/80 in adipose tissue was performed as described by the manufacturer's instructions. Sections (5 μm) were incubated overnight at 4 °C with rat anti-F4/80 antibody (cat. Ab16911, diluted 1:1,000; Abcam, Cambridge, UK) and incubated for 1 h with the appropriate secondary antibody. Image-Pro Plus version 6.0 software (Media Cybernetics, Silver Spring, MD, USA) was used to perform the analysis.

Quantitative real-time PCR
--------------------------

Real-time PCR was performed using RNA extracted from SAT and VAT of the experimental mice. RNA was isolated using TRIzol reagent (cat. 15596026; Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Total RNA was then converted into cDNA using a cDNA reverse transcription kit (TAKARA Bio Inc., Otsu, Shiga, Japan). Real-time PCR was performed using the SYBR Green detection system on an ABI PRISM 7900 machine (Applied Biosystems, Foster City, CA, USA) under the same conditions: one cycle of 95 °C, 5 s; 40 cycles of 95 °C, 10 s and 57 °C, 30 s. Gene expression levels were calculated using the 2^−▵▵△△CT^ method, and β-actin was used as an endogenous control gene. The sequences are listed in [Table 2](#table-2){ref-type="table"}.
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###### Primer sequences used for real-time PCR.
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  Gene        Forward primer (5′--3′)   Reverse primer (5′--3′)
  ----------- ------------------------- --------------------------
  *CCR2*      TCATCCACGGCATACTATCAACA   GTGGCCCCTTCATCAAGCT
  *MCP-1*     CCACTCACCTGCTGCTACTCA     TGGTGACCTCTTGTAGCTCTCC
  *TNF-α*     CCCAGACCCTCACACTCAGATC    GCCACTCCAGCTGCTCCTC
  *IL-6*      CTGCAAGAGACTTCCATCCAGTT   AGGGAAGGCCGTGGTTGT
  *F4/80*     CTTTGGCTATGGGCTTCCAGTC    GCAAGGAGGACAGAGTTTATCGTG
  *GLUT4*     CCCTGTTACCTCCAGGTTG       CCTTGCCCTGTCAGGTATGT
  *IRS-1*     GCCAATCTTCATCCAGTTGC      CATCGTGAAGAAGGCATAGG
  *β-actin*   TTCGTTGCCGGTCCACACCC      GCTTTGCACATGCCGGAGCC

**Note:**

CCR2, CC-chemokine receptor 2; MCP-1, monocyte chemo-attractant protein 1; TNF-α, tumor necrosis factor α; IL-6, interleukin-6; GLUT4, glucose transporter 4; IRS-1, insulin receptor substrate.

Western blot analysis
---------------------

Subcutaneous adipose tissue and VAT were homogenized with RIPA protein extraction reagent (cat. P0013B; Beyotime, Jiangsu, China) on ice. Equal quantities of protein were loaded and separated on a 10% and 7.5% SDS--PAGE gels. After electrophoresis, proteins were transferred to immobilon-P polyvinylidene difluoride membranes and blocked with 5% nonfat milk. Then, the membranes were immunoblotted with different primary antibodies: CCR2 (dilution, 1:2,000), IRS-1 (diluted 1:1,000), GLUT4 (diluted 1:1,000), Akt (diluted 1:1,000), pAkt (phosphorylated at Ser^473^) (diluted 1:2,000) and β-actin (diluted 1:10,000; Sigma-Aldrich, St. Louis, MO, USA). After the membranes were washed, the immunoblots were incubated with a secondary antibody conjugated with horseradish peroxidase, visualized with an ECL detection system (Syngen, Cambridge, UK) and analyzed using ChemiDoc Quantity One software (Bio-Rad Laboratories, Milan, Italy). β-actin was used as a loading control for CCR2, and pAkt was normalized to Akt.

Statistical analyses
--------------------

The data are shown as the mean ± SD. All statistical analyses were conducted using SPSS13.0 (SPSS, Chicago, IL, USA). Repeated measures ANOVA, with time (week) and diet (STD or HFD) as repeated measures were used to analyze body weight. The Greenhouse--Geisser test was used to revise degrees of freedom when Mauchly's test of sphericity showed *P* \< 0.05. The body weight gain, SAT coefficient, VAT coefficient, serum TG, serum TC, serum HDL, serum LDL, serum MCP-1, serum TNF-α, serum IL-6, AUC, ISI, HOMA-IR, and serum glucose at different time points in the IPGTT, as well as mRNA and protein expression levels were analyzed for statistical significance by one-way ANOVA followed by post hoc analysis (Bonferroni post-test). A value of *P* \< 0.05 was considered significant.

Results
=======

Effects of RES treatment on body weight curve, body weight gain and SAT/VAT coefficient
---------------------------------------------------------------------------------------

As shown in [Fig. 1](#fig-1){ref-type="fig"}, after 18 weeks of treatment, the HFD-fed mice had significantly increased body weight compared to that of the STD-fed mice (*P* \< 0.01), and there was no significant difference in body weight gain between the HFD group and the RES-treated groups (*P* \> 0.05). The SAT coefficient and VAT coefficient in the HFD-fed groups were significantly higher than those in the STD-fed group (*P* \< 0.01). RES treatment significantly decreased the SAT coefficient in the HFD-fed mice (*P* \< 0.05). However, RES treatment did not affect the VAT coefficient in the HFD-fed mice (*P* \> 0.05).

![Effects of RES treatment on body weight curve, body weight gain and subcutaneous/visceral adipose coefficients of mice in response to resveratrol treatment.\
(A) Body weight curve; (B) Body weight gain; (C) SAT coefficient; (D) VAT coefficient. ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 vs. the HFD group. Time\*\* indicates exposure duration. Diet\*\* indicates the variety of diet. Time × diet\*\* indicates the interaction effect between treatment duration and variety of diet. Data are expressed as the mean ± SD.](peerj-06-5173-g001){#fig-1}

Effects of RES treatment on glucose homeostasis in mice
-------------------------------------------------------

To assess the effects of RES treatment on glucose tolerance in HFD-fed mice, we measured blood glucose levels at different time points during the IPGTT after the 17-week treatment. As shown in [Fig. 2](#fig-2){ref-type="fig"}, the blood glucose levels of the HFD group displayed a marked increase compared with those of the STD group at all time points and compared with those of the HFD-RES/L group and HFD-RES/H group at 0, 15 and 30 min (*P* \< 0.01). The AUC was significantly increased in the HFD groups vs. that in the STD group (*P* \< 0.01). Moreover, the AUC was significantly decreased in the RES-treated groups when compared to that in the HFD group (*P* \< 0.01 or *P* \< 0.05). Compared to those in the STD group, significantly increased HOMA-IR values (*P* \< 0.01) and significantly decreased insulin sensitivity were observed in the HFD-fed groups (*P* \< 0.01). Furthermore, compared to those in the HFD group, significantly decreased HOMA-IR values (*P* \< 0.05) and increased ISI were observed in the HFD-RES/H group (*P* \< 0.05).

![Effects of resveratrol treatment on glucose homeostasis in mice.\
(A) Blood glucose during IPGTT after 17-week treatment; (B) AUC of IPGTT; (C) HOMA-IR; (D) Insulin sensitivity index.](peerj-06-5173-g002){#fig-2}

Effects of RES treatment on serum metabolic parameters
------------------------------------------------------

[Figure 3](#fig-3){ref-type="fig"} shows the serum metabolic parameters and hepatic lipid levels after HFD treatment and RES administration. The TG, TC and LDL levels in serum of the HFD-fed groups were significantly higher than those in the STD group (*P* \< 0.01). Furthermore, decreased serum HDL was observed in the HFD-fed groups compared to that in the STD group (*P* \< 0.01). In addition, RES (400 mg/kg/day) treatment significantly decreased the TG and TC levels in serum of the HFD-fed mice (*P* \< 0.01 or *P* \< 0.05). Compared to those in the HFD group, significantly increased serum HDL levels and decreased LDL levels were observed in the RES-treated groups (*P* \< 0.01 or *P* \< 0.05). No significant differences in TG, TC, HDL and LDL levels in the serum were observed between the HFD-RES/L group and HFD-RES/H group (*P* \> 0.05).

![Effects of resveratrol treatment on serum metabolic parameters.\
(A) Serum TG; (B) Serum TC; (C) Serum HDL; (D) Serum LDL. ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 and ^bb^, *P* \< 0.01 vs. the HFD group. The data are represented as the mean ± SD.](peerj-06-5173-g003){#fig-3}

Effects of RES treatment on serum cytokines
-------------------------------------------

As shown in [Fig. 4](#fig-4){ref-type="fig"}, the levels of serum MCP-1, TNF-α and IL-6 in the HFD-fed groups were markedly increased compared to those in the STD group (*P* \< 0.01). RES (400 mg/kg/day) treatment decreased the serum MCP-1, TNF-α and IL-6 levels in the HFD groups (*P* \< 0.05 or *P* \< 0.01). However, the low dose of RES (200 mg/kg/day) treatment only decreased the serum MCP-1 level in HFD-fed mice (*P* \< 0.05).

![Effects of resveratrol treatment on serum cytokines.\
(A) MCP-1; (B) TNF-α; (C) IL-6. ^a^, *P* \< 0.05 and ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 and ^bb^, *P* \< 0.01 vs. the HFD group. The data are represented as the mean ± SD.](peerj-06-5173-g004){#fig-4}

Effects of RES treatment on mRNA and protein expression of a macrophage marker in SAT and VAT
---------------------------------------------------------------------------------------------

We used immunohistochemistry and real-time PCR with the macrophage marker F4/80 to assess the infiltration of total macrophages in SAT and VAT (See [Fig. 5](#fig-5){ref-type="fig"}). Significantly increased F4/80 mRNA and protein expression in SAT and VAT were observed in the HFD groups when compared to that in the STD group (*P* \< 0.01). Compared to that in the HFD group, the mRNA and protein expression of F4/80 was significantly decreased in RES-treated mice (*P* \< 0.05).

![Effects of resveratrol treatment on mRNA and protein expression levels of a macrophage marker in SAT and VAT.\
(A) Immunohistochemistry staining of F4/80 (total macrophages) in SAT and VAT; (B) quantitative expression of F4/80 (total macrophages) is shown as relative density in SAT and VAT; (C) the mRNA expression of F4/80 in SAT and VAT. Original magnification is ×200 (scale bar = 100 μm). ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 vs. the HFD group. The data are represented as the mean ± SD.](peerj-06-5173-g005){#fig-5}

Effects of RES treatment on mRNA expression in SAT and VAT of mice
------------------------------------------------------------------

As shown in [Fig. 6](#fig-6){ref-type="fig"}, we determined the effect of RES administration on the mRNA expression of inflammatory cytokines (*CCR2*, *MCP-1*, *TNF-α* and *IL-6*), *GLUT4* and *IRS-1* in SAT and VAT. Levels of *CCR2*, *MCP-1*, *TNF-α* and *IL-6* in SAT and VAT were significantly increased in the HFD groups compared to those in the STD group (*P* \< 0.01). RES administration significantly decreased the mRNA levels of *CCR2*, *MCP-1* and *IL-6* in SAT in the HFD mice compared to that in the HFD mice (*P* \< 0.01 or *P* \< 0.05). Moreover, RES administration significantly decreased the mRNA levels of *CCR2*, *MCP-1* and *TNF-α* in VAT in the HFD mice (*P* \< 0.01 or *P* \< 0.05). In contrast, the mRNA expression levels of *GLUT4* and *IRS-1* in SAT and VAT were markedly decreased in the HFD groups compared to those in the STD group (*P* \< 0.05). The mRNA expression of *GLUT4* in SAT was significantly increased by RES administration (*P* \< 0.01 or *P* \< 0.05). Furthermore, the mRNA expression of *GLUT4* and *IRS-1* in VAT was also markedly increased by RES administration (*P* \< 0.05).

![Effects of resveratrol treatment on the target mRNA expression in SAT and VAT.\
(A) The mRNA levels of inflammatory cytokines (*CCR2*, *MCP-1*, *TNF-α* and *IL-6*); (B) the mRNA levels of *GLUT4* and *IRS-1* in SAT; (C) the mRNA levels of inflammatory cytokines (*CCR2*, *MCP-1*, *TNF-α* and *IL-6*) in VAT; (D) the mRNA levels of *GLUT4* and *IRS-1* in VAT. ^a^, *P* \< 0.05 and ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 and ^bb^, *P* \< 0.01 vs. the HFD group. The data are represented as the mean ± SD.](peerj-06-5173-g006){#fig-6}

Effects of RES treatment on protein expression levels in SAT and VAT in mice
----------------------------------------------------------------------------

Changes in protein expression of CCR2, GLUT4, IRS-1 and pAkt were measured using Western blot analysis (see [Fig. 7](#fig-7){ref-type="fig"}). CCR2 protein expression was markedly increased in SAT and VAT in the HFD group compared to that in the STD group (*P* \< 0.05). RES administration significantly decreased CCR2 protein expression in SAT and VAT of the HFD groups (*P* \< 0.01 or *P* \< 0.05). Compared to the STD group, decreased protein expression of IRS-1 and GLUT4 in SAT and VAT in the HFD groups was observed (*P* \< 0.05), and RES administration significantly increased expression of IRS-1 and GLUT4 in SAT and VAT (*P* \< 0.01 or *P* \< 0.05). Furthermore, the protein expression of IRS-1 in the HFD-RES/H group was higher than that in the other three groups (*P* \< 0.01 or *P* \< 0.05). In addition, the results showed that the protein expression of pAkt in SAT in the HFD group was lower than that in the STD group (*P* \< 0.01), and the protein expression of pAkt in SAT in the HFD-RES/H group was higher than that in in the HFD group (*P* \< 0.01). Similarly, the protein expression of pAkt in SAT in the HFD-RES/H group was higher than that in the HFD group (*P* \< 0.01).

![Effects of resveratrol treatment on the protein expression of CCR2, IRS-1, pAkt (phosphorylation at Ser ^473^) and GLUT4 in SAT and VAT.\
(A) Western blots of CCR2 and insulin signaling molecules in SAT; (B) Western blots of CCR2 and insulin signaling molecules in VAT; (C--F) CCR2, IRS-1, pAkt and GLUT4 protein expression levels in SAT; (G--J) CCR2, IRS-1, pAkt and GLUT4 protein expression levels in VAT. ^a^, *P* \< 0.05 and ^aa^, *P* \< 0.01 vs. the STD group; ^b^, *P* \< 0.05 and ^bb^, *P* \< 0.01 vs. the HFD group; ^c^, *P* \< 0.05 vs. the HFD-RES/L group. The data are represented as the mean ± SD.](peerj-06-5173-g007){#fig-7}

Discussion
==========

Our study indicates that CCR2 in WAT may play a critical role in macrophage infiltration and the inflammatory response during the development of insulin resistance in HFD-induced obese mice. Our study further demonstrated that RES administration could reverse insulin resistance, decrease CCR2 expression in SAT and VAT, and reduce inflammation and macrophage infiltration of SAT and VAT, thus increasing insulin signaling molecules (such as IRS-1, GLUT4 and pAkt) in HFD-induced obese mice.

Macrophage infiltration into adipose tissues is characteristic of chronic inflammation associated with obesity. Recently, chemokine receptors (such as CCR2) have been proposed to be attractive targets for antiobesity. They interact with their ligands, increasing inflammatory cells in adipose tissue, and further contribute to chronic inflammation and insulin resistance in obesity ([@ref-29]). Increasing evidence has shown that CCR2 could promote the macrophage recruitment and infiltration of tissue in the pathogenesis of insulin resistance ([@ref-17]; [@ref-19]). Thus, we studied the role of CCR2 in SAT and VAT during the development of insulin resistance related to obesity. Consistent with the increased expression of serum inflammatory cytokines (such as MCP-1, TNF-α and IL-6) in obese mice, we demonstrated that the expression of CCR2 and macrophage infiltration in SAT and VAT were significantly increased in diet-induced obese mice. This was also observed in other studies of WAT in diet-induced obese rodent models ([@ref-22]; [@ref-40]). In vitro, RES inhibited the mRNA and protein expression in CCR2 of THP-1 monocytes ([@ref-7]). Here, we found that concomitant with a decrease in CCR2 expression and total macrophage F4/80 in SAT and VAT, proinflammatory cytokines in serum and mRNA levels of inflammatory cytokines in WAT were significantly reduced in RES-treated obese mice. These results suggest that CCR2 expression decreased by RES treatment may play a vital role in the reduced migration of total macrophages and subsequent inflammation in adipose tissues.

In population experiments, whether RES administration could improve glucose metabolism disorder is inconclusive. Studies performed in patients with T2DM ([@ref-2]) and healthy obese men ([@ref-38]) observed the beneficial effects of RES administration for three months and four weeks, respectively, on systemic insulin sensitivity. However, another study conducted in normal-weight, healthy individuals did not demonstrate improved glucose metabolism after RES administration for six weeks ([@ref-13]). These contradictory results indicate that RES treatment may have a beneficial effect on glucose metabolism disorders in obese individuals rather than normal-weight individuals, and excess adipose tissues may be the target for RES for alleviating disordered glucose mechanisms in individuals. In our study, we observed that RES administration significantly reduced the AUC, improved HOMA-IR and increased insulin sensitivity in HFD-induced obese mice, which suggests that RES improved glucose intolerance and glucose homeostasis. In corroboration with our findings, some rodent studies have also reported that RES treatment ameliorated insulin resistance in HFD animals for eight weeks ([@ref-5]; [@ref-14]). Long-term IL-6 or TNF-α treatment inhibits the expression of GLUT4 and IRS-1 in adipose tissue ([@ref-16]; [@ref-34]), and in obese patients with T2DM, lower levels of GLUT4 and IRS-1 in VAT were observed ([@ref-12]; [@ref-25]). In addition, glucose disposal in WAT is affected by misleading insulin signaling via a reduction in the PI3K/pAkt signaling pathway ([@ref-28]). The above results indicate that inflammatory cytokines contribute substantially to driving the abnormal insulin signaling cascade of WAT in obesity, leading to a worsening of whole-body insulin resistance and glucose intolerance. Our results demonstrated that long-term RES administration alleviated abnormal insulin signaling cascades in WAT of HFD-induced obese mice by increasing the levels of IRS-1 and GLUT4 and enhancing the phosphorylation level of the Akt protein. In line with our findings, [@ref-18] also found that chronic administration of RES exerts an anti-inflammatory effect and improves adipose insulin signaling in adipose tissue of high-fat, high-sugar diet-fed rhesus monkeys. Moreover, improved insulin resistance via inhibition of TNF-α and TNF-α-mediated inflammation by RES treatment were observed in 3T3-L1 adipocytes ([@ref-42]) and in primary human adipocytes ([@ref-6]). In this paper, we showed that RES administration for 18 weeks markedly decreased the SAT coefficient and prevented dyslipidemia in HFD-fed mice. In agreement with our study, [@ref-4] also reported that RES (400 mg/kg/day) treatment for three months provided protection against diet-induced dyslipidemia in C57BL/6 mice. Studies have demonstrated that RES treatment has fat mobilization and antiobesity effects in rodents ([@ref-1]), and also significantly reduced the body weight gain of female Wistar rats and ovariectomized female Wistar rats ([@ref-36]). In this study, we observed that the RES intervention did not significantly reduce the body weight of mice; however, we detected a trend of reduced body weight in mice treated with RES.

Conclusion
==========

In conclusion, our results indicate that RES administration could increase CCR2 expression in WAT, alleviate inflammation and macrophage infiltration to improve the expression of classical markers of the insulin signaling cascade in SAT and VAT, and maintain glucose metabolic homeostasis in diet-induced obese mice. Thus, the current study highlights the potential clinical utility of RES administration in attenuating macrophage-induced inflammation in adipose tissue and preventing obesity-related metabolic diseases.
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